Leriglitazone

Leriglitazone was a prescription medication belonging to a class of drugs called thiazolidinediones (TZDs). It was used to treat type 2 diabetes, but it's no longer commonly prescribed due to safety concerns. Here's a breakdown of what you need to know:

Function: Leriglitazone worked by improving insulin sensitivity in the body's cells. Insulin is a hormone that helps cells absorb glucose (sugar) from the bloodstream for energy. By enhancing insulin sensitivity, Leriglitazone helped to lower blood sugar levels in people with type 2 diabetes.

Past Applications: Leriglitazone was previously prescribed in combination with other medications or lifestyle changes for managing type 2 diabetes in adults.

Reasons for Withdrawal:

  • Increased cardiovascular risks: Studies revealed an association between Leriglitazone use and an increased risk of heart failure, congestive heart failure, and other cardiovascular complications. These risks outweighed the potential benefits of blood sugar control for many patients.
  • Regulatory actions: Due to safety concerns, regulatory bodies like the US Food and Drug Administration (FDA) issued warnings and restrictions on Leriglitazone use. Eventually, some manufacturers withdrew the medication from the market.

Current Treatment Options for Type 2 Diabetes:

Several other medications and treatment approaches are available for type 2 diabetes management, including:

  • Metformin: This is often the first-line medication for type 2 diabetes, helping to control blood sugar levels and improve insulin sensitivity.
  • Sulfonylureas: These medications stimulate the pancreas to release more insulin.
  • DPP-4 inhibitors: These drugs work by incretins, hormones that promote insulin release and suppress glucagon secretion (glucagon raises blood sugar levels).
  • SGLT2 inhibitors: These medications help the kidneys remove excess sugar from the body through urine.
  • GLP-1 receptor agonists: These injectable medications mimic the effects of a natural gut hormone that promotes insulin release, reduces glucagon secretion, and slows down digestion.
Anatomical Therapeutic Chemical Classification
A - Alimentary tract and metabolism
A16 Other alimentary tract and metabolism products
A16A - Other alimentary tract and metabolism products
QA16AX Various alimentary tract and metabolism products
External Links